Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 1621 | 0.095 |
09:36 ET | 49332 | 0.095 |
09:38 ET | 100000 | 0.095 |
09:52 ET | 5600 | 0.0935 |
09:54 ET | 400 | 0.092 |
09:57 ET | 200 | 0.092 |
09:59 ET | 12700 | 0.092 |
10:03 ET | 100 | 0.092 |
10:15 ET | 10000 | 0.0932 |
10:33 ET | 146 | 0.092 |
11:18 ET | 100 | 0.092 |
11:44 ET | 3400 | 0.092 |
12:09 ET | 200 | 0.092 |
12:14 ET | 250 | 0.09305 |
12:23 ET | 100 | 0.092 |
12:38 ET | 1350 | 0.093 |
01:15 ET | 2191 | 0.092 |
02:04 ET | 5000 | 0.095 |
02:09 ET | 200 | 0.092 |
02:11 ET | 200 | 0.092 |
02:13 ET | 100 | 0.092 |
03:09 ET | 100 | 0.092 |
03:12 ET | 200 | 0.092 |
03:14 ET | 100 | 0.092 |
03:16 ET | 100 | 0.092 |
03:18 ET | 100 | 0.092 |
03:20 ET | 100 | 0.092 |
03:21 ET | 400 | 0.092 |
03:23 ET | 100 | 0.092 |
03:25 ET | 100 | 0.092 |
03:27 ET | 100 | 0.092 |
03:30 ET | 200 | 0.092 |
03:32 ET | 100 | 0.093 |
03:34 ET | 200 | 0.093 |
03:36 ET | 200 | 0.092 |
03:38 ET | 100 | 0.092 |
03:39 ET | 1200 | 0.092 |
03:41 ET | 200 | 0.093 |
03:43 ET | 200 | 0.092 |
03:45 ET | 200 | 0.092 |
03:48 ET | 300 | 0.093 |
03:50 ET | 200 | 0.092 |
03:52 ET | 500 | 0.092 |
03:54 ET | 119684 | 0.095 |
03:56 ET | 9199 | 0.092 |
03:57 ET | 1100 | 0.092 |
03:59 ET | 1100 | 0.092 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.6M | 0.0x | --- |
Altamira Therapeutics Ltd | 3.3M | -0.1x | --- |
Bio Path Holdings Inc | 3.6M | -0.1x | --- |
Avenue Therapeutics Inc | 3.6M | -0.1x | --- |
Biophytis SA | 3.3M | -0.1x | --- |
Zyversa Therapeutics Inc | 3.5M | 0.0x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.